English Korean Chinese
ホーム > 市場調査レポート > 医薬品 > 精神疾患 > 注意欠陥多動性障害(ADHD)市場の予測
カテゴリ
医薬品 (4955)
OTC (153)
がん (943)
ドラッグデリバリー (185)
ワクチン (182)
感染症 (351)
規制環境 (130)
後発医薬品 (134)
骨疾患 (37)
処方薬 (157)
神経疾患 (174)
精神疾患 (88)
製薬企業関連 (531)
創薬 (1523)
糖尿病 (192)
動物用医薬 (17)
肥満症 (44)
市場調査レポート

注意欠陥多動性障害(ADHD)市場の予測

Attention-Deficit Hyperactivity Disorder Market Forecast

発行 Datamonitor
出版日 2009年07月 商品コード 97335
ページ情報 英文  
価格
US$ 15,200 換算 ¥ 1,226,488 (税抜) Excel file by E-mail (Single User License)
US$ 38,000 換算 ¥ 3,066,220 (税抜) Excel file by E-mail (Global Site License)


原文目次

Abstract

Introduction

Driven primarily by continued uptake of Shire' s market leading ADHD drug, Adderall XR (amphetamine extended release), seven major market ADHD revenues grew strongly at a compound annual growth rate (200408) of 13.5% to reach almost $4.4 billion in 2008. Ongoing uptake of Shire' s Vyvanse (lisdexamfetamine), was also a key contributor to market growth between 2007 and 2008.

Key reasons to purchase this research

  • This report gives a strategic analysis of the likely impact that recent events will have on the future ADHD market.
  • Includes sales forecasts for the key ADHD brands and generics as well as pipeline agents in the seven major markets to 2018.
  • Quantify the current and future size of the seven major ADHD markets.

Table of Contents

OVERVIEW

  • This product contains forecasts for attention-deficit hyperactivity disorder (ADHD) drugs across the seven major markets from 2009 to 2018. It has been designed for delivery in an excel data pack format.
    • The associated report can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative.
    • Introduction
    • Scope of this research
    • Research and analysis highlights
    • Key reasons to read this report
  • Forecasting Methodology
    • The forecasting model:
    • General event information:
    • Event selection and quantification:
    • Event parameters:
Back to Top